Earnings Call Intelligence Subscribe
Home › Call Sheets › BIIB › Q4'25
Call sheet · Q4'25

Biogen (BIIB)

Q4'25 earnings call · held February 6, 2026 · compared with the Q3'25 call · management-credibility review
11/12
Disclosure score
3 medium, 5 low flags
Financial quality
Bottom line
The sleeper story is VUMERITY's stealth transformation into a $747M growth engine with patent protection through 2030, now officially classified as a growth product rather than declining legacy MS. While everyone focuses on Leqembi's growth trajectory, VUMERITY could be the quiet cash cow funding the pipeline transition. The binding constraint isn't demand but execution risk across 10 simultaneous Phase III programs with a threadbare early pipeline behind them. Chris admitted 'we do need to build up our earlier stage pipeline' - if even two of these late-stage programs fail, there's a cliff after 2028. My view changes if they can articulate specific peak sales estimates for the lupus/nephrology portfolio or announce a transformative BD deal filling the early pipeline gap.

The 30-second version

  • VUMERITY quiet cash cow - now officially a 'growth product' generating $747M at 19% growth
  • Leqembi subcutaneous for induction could be the real catalyst - not just convenience, it's competitive repositioning
  • Late-stage pipeline is front-loaded with registrational readouts but early-stage is still threadbare

What changed this quarter

MetricQ3'25Q4'25Change
Total Revenue$7.75B (Q3, up 3% YoY)$9.9B (FY, up 2% YoY)Slight deceleration in growth momentum
Growth Products Revenue$630M (Q3, up 67% YoY)$3.3B (FY, up 19% YoY)Now includes VUMERITY, absolute growth strong
Non-GAAP Diluted EPSNot specified Q3$15.28 (FY vs guidance $15.25-$16.25)Beat at upper end of range
Leqembi Global Revenue$121M (Q3)$134M (Q4, up 1054% YoY)Sustained sequential growth trajectory
VUMERITY RevenueNot broken out Q3$747M (FY, up 19% YoY)Now classified as growth product, strong momentum
MS Revenue ex-VUMERITYResilient performance$3B (still generating)Holding better than expected
SPINRAZA RevenueNot specified Q3$356M (Q4, down 2% FY)Resilient in competitive market
Skyclaris Revenue$119M (Q3, 30% growth YoY)$133M (Q4, 30% growth YoY)Consistent growth despite pricing headwinds
TECFIDERA EU Erosion$28M sequential decline Q3Full year erosion acceleratingExpect double Q4 vs Q3 erosion going forward
Free Cash Flow$1.2B (Q3)$2.1B (FY)Strong cash generation maintained

Accountability tracked

8 new promises made6 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full BIIB Q4'25 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.